Literature DB >> 23551096

Achieving cancer cell death with PI3K/mTOR-targeted therapies.

Sung Su Yea1, David A Fruman.   

Abstract

Inhibitors of the PI3K/mTOR signaling network are under development as novel cancer therapies. However, these compounds do not cause robust cytotoxic responses in tumor cells unless combined with other agents. Rational combinations with other targeted therapies will likely be necessary to achieve the potential of PI3K/mTOR inhibitors in oncology.
© 2013 New York Academy of Sciences.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23551096      PMCID： PMC3621026          DOI： 10.1111/nyas.12028

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

3.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors:  Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal:  Nat Med       Date:  2010-01-13       Impact factor: 53.440

Review 4.  Emerging epigenetic targets and therapies in cancer medicine.

Authors:  Relja Popovic; Jonathan D Licht
Journal:  Cancer Discov       Date:  2012-04-23       Impact factor: 39.397

Review 5.  PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.

Authors:  David A Fruman; Christian Rommel
Journal:  Cancer Discov       Date:  2011-11-29       Impact factor: 39.397

6.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jing Deng; Adrian Wiestner; Brian J Lannutti; Lili Wang; Catherine J Wu; Wyndham H Wilson; Jennifer R Brown; Anthony Letai
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

Review 7.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

8.  Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Authors:  Celina García-García; Yasir H Ibrahim; Violeta Serra; Maria Teresa Calvo; Marta Guzmán; Judit Grueso; Claudia Aura; José Pérez; Katti Jessen; Yi Liu; Christian Rommel; Josep Tabernero; José Baselga; Maurizio Scaltriti
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 13.801

9.  Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Authors:  M R Janes; C Vu; S Mallya; M P Shieh; J J Limon; L-S Li; K A Jessen; M B Martin; P Ren; M B Lilly; L S Sender; Y Liu; C Rommel; D A Fruman
Journal:  Leukemia       Date:  2012-10-01       Impact factor: 12.883

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
  10 in total
  11 in total

1.  PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.

Authors:  Mukund Patel; Nicholas C Gomez; Andrew W McFadden; Billie M Moats-Staats; Sam Wu; Andres Rojas; Travis Sapp; Jeremy M Simon; Scott V Smith; Kathleen Kaiser-Rogers; Ian J Davis
Journal:  Mol Cancer Res       Date:  2014-07-03       Impact factor: 5.852

2.  mTOR Inhibitors at a Glance.

Authors:  Yin Zheng; Yu Jiang
Journal:  Mol Cell Pharmacol       Date:  2015

Review 3.  Microbial genome mining for accelerated natural products discovery: is a renaissance in the making?

Authors:  Brian O Bachmann; Steven G Van Lanen; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2013-12-17       Impact factor: 3.346

4.  Protective Effect of DHT on Apoptosis Induced by U18666A via PI3K/Akt Signaling Pathway in C6 Glial Cell Lines.

Authors:  Kai Yao; Junfeng Wu; Jianfeng Zhang; Jimei Bo; Zhen Hong; Hengbing Zu
Journal:  Cell Mol Neurobiol       Date:  2015-09-04       Impact factor: 5.046

5.  Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.

Authors:  Iván Roa; Gonzalo de Toro; Fernanda Fernández; Anakaren Game; Sergio Muñoz; Xabier de Aretxabala; Milind Javle
Journal:  Diagn Pathol       Date:  2015-08-21       Impact factor: 2.644

6.  Ethanol Extract of Hizikia fusiforme Induces Apoptosis in B16F10 Mouse Melanoma Cells through ROS-Dependent Inhibition of the PI3K/Akt Signaling Pathway.

Authors:  Cheol Park; Hyesook Lee; Hyun Hwangbo; Seon Yeong Ji; Min Yeong Kim; So Young Kim; Su Hyun Hong; Gi-Young Kim; Yung Hyun Choi
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 7.  Autophagy Regulation and Photodynamic Therapy: Insights to Improve Outcomes of Cancer Treatment.

Authors:  Waleska K Martins; Renata Belotto; Maryana N Silva; Daniel Grasso; Maynne D Suriani; Tayná S Lavor; Rosangela Itri; Mauricio S Baptista; Tayana M Tsubone
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

8.  β-lapachone-Induced Apoptosis of Human Gastric Carcinoma AGS Cells Is Caspase-Dependent and Regulated by the PI3K/Akt Pathway.

Authors:  Hai Yang Yu; Sung Ok Kim; Cheng-Yun Jin; Gi-Young Kim; Wun-Jae Kim; Young Hyun Yoo; Yung Hyun Choi
Journal:  Biomol Ther (Seoul)       Date:  2014-05       Impact factor: 4.634

9.  miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.

Authors:  Jun Chen; Chao Zhou; Junhe Li; Xiaojun Xiang; Ling Zhang; Jun Deng; Jianping Xiong
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

10.  Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification.

Authors:  Daniel Toro-Domínguez; Raúl Lopez-Domínguez; Adrián García Moreno; Juan A Villatoro-García; Jordi Martorell-Marugán; Daniel Goldman; Michelle Petri; Daniel Wojdyla; Bernardo A Pons-Estel; David Isenberg; Gabriela Morales-Montes de Oca; María Isabel Trejo-Zambrano; Benjamín García González; Florencia Rosetti; Diana Gómez-Martín; Juanita Romero-Díaz; Pedro Carmona-Sáez; Marta E Alarcón-Riquelme
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.